Surname and Name
La Regina Giuseppe
Current Position
Since September 2019: Associate Professor in Medicinal Chemistry, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma.
Main Scientific Interests
Design, synthesis and development of anti-infective (human immunodeficiency virus 1, Rhinovirus, hepatitis C virus, Dengue virus, Mycobacterium tuberculosis and Candida albicans), anti-cancer (tubulin, apoptosis, histone demethylase, matrix metalloproteinases, BCL-2 family members, Frizzled4, carbonic anhydrase, indoleamine 2,3-dioxygenase 1, MDM2/MDM4, NHERF-1) and central nervous system active (monoamine oxidases, endocannabinoid system, glycogen synthase kinase 3 beta) agents; microwave-assisted organic synthesis; molecular modelling studies.
Work Experience
March 2007 - November 2008: Design, synthesis and development of new inhibitors of tubulin polymerization as anticancer agents, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma (3-year grant financed by AIRC/FIRC, Milan, Italy).
April 2005 - March 2007: Molecular modelling studies to design new inhibitors of tubulin polymerization as anticancer agents, postdoctoral position, Welsh School of Pharmacy, Cardiff University, UK, (2-year grant financed by Institut Pasteur - Cenci Bolognetti Foundation, Rome, Italy).
November 2001 - October 2004: PhD course in Medicinal Chemistry, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma.
Education
Italian Level 2 Master in Drug Design and Development: May 2007, Università degli Studi di Pavia, Pavia, Italy.
PhD in Medicinal Chemistry: March 2005, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma.
Graduation in Pharmacy: July 2001, full marks, Faculty of Pharmacy, Sapienza Università di Roma.
Scientific Publications
Co-Author of more than 100 scientific papers and 5 patents (h-index: 33; overall citations: 3900; Scopus, https://www.scopus.com/authid/detail.uri?authorId=6602306518).
Congresses, Meetings and Workshops
15 oral and ore than 100 poster communications in national and international meetings; member of scientific and organizing committees in national and international meetings.
Examinations and Awards
2017: Qualifying examination for Full Professor in Medicinal Chemistry (03/D1, D.D. n. 1532/2016).
2014: Qualifying examination for Associate Professor in Medicinal Chemistry (03/D1, D.D. n. 222/2012).
2007: Farmindustria Prize for Pharmaceutical Research - Outstanding for researching activity.
Teaching Activity
Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma: a) Professor of Inorganic Drug Analysis; b) Professor of Acquisition of IT Skills and Monitoring of Prescriptions and Analysis of Drug Consumption in Hospital; c) Professor of Nutraceutical Principles; d) member of examination committee in Medicinal Chemistry courses; e) member of examination committee of graduating students in Pharmacy and Chimica e Tecnologia Farmaceutiche (Pharmaceutical Chemistry and Technology); f) member of examination committee of PhD students in Medicinal Chemistry (Doctor Europaeus); g) tutor of graduating students in Pharmacy and Chimica e Tecnologia Farmaceutiche; h) supervisor/tutor of PhD students in Medicinal Chemistry.
Facoltà di Medicina e Chirurgia “A. Gemelli”, Corso di Laurea in Farmacia, Rome: Professor of Quantitative Analysis of Drugs (10 CFU) and Qualitative Analysis of Drugs (5 CFU).
Principal Investigator of Funded Research Projects
Finanziamenti di Ateneo 2023, Sapienza Università di Roma: Tubulin inhibitors as ferroptosis inducers in cancer treatment; RG123188B4D193AE; 18 months, 60840 euro.
Bando PRIN 2022, Ministero dell'Università e della Ricerca: Targeting Wnt/beta-catenin pathway: identification and development of selective allosteric modulators of Dishevelled and Frizzled proteins as a promising approach to cancer therapy (INdWNT); 2022TPPNTK; 24 months, 203748 euro.
Finanziamenti di Ateneo 2019, Sapienza Università di Roma: Treatment of chronic myeloid leukemia by inhibition of tubulin polymerization; RM11916B5598E3C4; 18 months, 14500 euro.
Call 2019, Istituto Pasteur – Fondazione Cenci Bolognetti: Treatment of chronic myeloid leukemia by inhibition of tubulin polymerization; 24 months, 40000 euro.
Finanziamento delle attività base di ricerca 2017, Agenzia Nazionale di Valutazione del Sistema Universitario e della Ricerca, 3000 euro.
Finanziamenti di Ateneo 2017, Sapienza Università di Roma, Hit to lead optimization of arylthioindoles and aroylindoles as modern anticancer agents, RP11715C7D1CF0D1, 18 months, 4000 euro.
Finanziamenti Ateneo 2016, Sapienza Università di Roma, Targeting colchicine binding site of tubulin by indole- and pyrrole-based anticancer agents, RG116154CF287B95, 18 months, 30000 euro.
Ricerche Universitarie 2015, Sapienza Università di Roma, New inhibitors of tubulin polymerization as anticancer agents endowed with stimulation of natural killer cell cytotoxic activity and repression of Hedgehog signalling pathway, C26A15J3BB, 18 months, 34450 euro.
Ricerche Universitarie 2014, Sapienza Università di Roma, Development of new compounds as anticancer and analgesic agents, C26A14TLFT, 18 months, 20000 euro.
Progetti Awards Ricerche Universitarie 2013, Sapienza Università di Roma, Tubulin and TRP channels as targets for new antitumor and analgesic agents, C26H135FL5, 18 months, 55000 euro.
Università degli Studi di Roma “La Sapienza”, Congressi e convegni 2013, XXII National Meeting on Medicinal Chemistry, C26C12KS92, 18 months, 3500 euro.
FIRB Futuro in Ricerca 2010, Ministero dell’Istruzione, dell’Università e della Ricerca, Mitochondrial medicinal chemistry against cell death-resistant cancers, RBFR10ZJQT_003, 36 months, 307671 euro.